Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
CAR-T therapy, best known for fighting blood cancers, is now being explored as a way to clear out "zombie" senescent cells that accumulate with age and drive conditions like diabetes, Alzheimer's, and liver fibrosis. A single dose in mice lasted over 15 months, outperforming conventional drugs that require repeat dosing. Researchers are still working to ensure the therapy can precisely target harmful cells without damaging healthy ones.
CAR-T cell therapy — the immunotherapy that revolutionized blood cancer treatment — may have a surprising new frontier: aging itself. Researchers are engineering these immune cells to hunt down senescent cells, the so-called "zombie cells" that accumulate in tissues over time and fuel chronic inflammation, metabolic dysfunction, and diseases like Alzheimer's, liver fibrosis, and diabetes.
The most exciting early results come from targeting a protein called uPAR, which is overexpressed on many senescent cells. In mouse studies, a single dose of uPAR-targeting CAR-T cells persisted for over 15 months, improving glucose tolerance, exercise capacity, gut health, and reducing age-related metabolic dysfunction — a durability that far surpasses conventional senolytic drugs requiring repeated dosing.
Key Takeaways:
Why it matters: Aging drives the majority of chronic disease burden globally. If CAR-T therapy can safely and precisely clear harmful senescent cells, it could offer a transformative, long-lasting intervention — but researchers must first solve the challenge of distinguishing cells that need to be eliminated from those the body still needs.
